Ligand pharmaceuticals incorporatedLGND.US Overview
LGND Overall Performance
LGND AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
LGND Key Information
LGND Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
LGND Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
LGND Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Price of LGND
LGND FAQ
When is LGND's latest earnings report released?
The most recent financial report for Ligand pharmaceuticals incorporated (LGND) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LGND's short-term business performance and financial health. For the latest updates on LGND's earnings releases, visit this page regularly.
Where does LGND fall in the P/E River chart?
According to historical valuation range analysis, Ligand pharmaceuticals incorporated (LGND)'s current price-to-earnings (P/E) ratio is 82.03, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of LGND?
According to the latest financial report, Ligand pharmaceuticals incorporated (LGND) reported an Operating Profit of 54.93M with an Operating Margin of 47.58% this period, representing a growth of 1,647.73% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is LGND's revenue growth?
In the latest financial report, Ligand pharmaceuticals incorporated (LGND) announced revenue of 115.46M, with a Year-Over-Year growth rate of 122.85%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does LGND have?
As of the end of the reporting period, Ligand pharmaceuticals incorporated (LGND) had total debt of 451M, with a debt ratio of 0.31. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does LGND have?
At the end of the period, Ligand pharmaceuticals incorporated (LGND) held Total Cash and Cash Equivalents of 139.38M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does LGND go with three margins increasing?
In the latest report, Ligand pharmaceuticals incorporated (LGND) achieved the “three margins increasing” benchmark, with a gross margin of 96.7%%, operating margin of 47.58%%, and net margin of 101.6%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LGND's profit trajectory and future growth potential.
Is LGND's EPS continuing to grow?
According to the past four quarterly reports, Ligand pharmaceuticals incorporated (LGND)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 5.99. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of LGND?
Ligand pharmaceuticals incorporated (LGND)'s Free Cash Flow (FCF) for the period is 13.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 63.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of LGND?
The latest valuation data shows Ligand pharmaceuticals incorporated (LGND) has a Price-To-Earnings (PE) ratio of 82.03 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.